Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-3,932
Closed -$240K 84
2017
Q3
$240K Hold
3,932
0.06% 112
2017
Q2
$240K Hold
3,932
0.06% 122
2017
Q1
$238K Buy
+3,932
New +$239K 0.06% 122
2016
Q4
Sell
-4,168
Closed -$244K 121
2016
Q3
$248K Sell
4,168
-1,790
-30% -$105K 0.06% 116
2016
Q2
$327K Hold
5,958
0.07% 124
2016
Q1
$300K Sell
5,958
-162
-3% -$7.93K 0.07% 129
2015
Q4
$308K Hold
6,120
0.07% 131
2015
Q3
$288K Hold
6,120
0.07% 133
2015
Q2
$332K Sell
6,120
-963
-14% -$54K 0.06% 122
2015
Q1
$389K Buy
7,083
+628
+10% +$35.6K 0.07% 114
2014
Q4
$350K Sell
6,455
-1,565
-20% -$87.2K 0.06% 122
2014
Q3
$453K Sell
8,020
-27
-0.3% -$1.52K 0.08% 104
2014
Q2
$444K Sell
8,047
-250
-3% -$13.6K 0.08% 100
2014
Q1
$449K Sell
8,297
-344
-4% -$17.8K 0.07% 103
2013
Q4
$413K Buy
8,641
+1,048
+14% +$47.9K 0.06% 111
2013
Q3
$345K Sell
7,593
-1,317
-15% -$60.1K 0.06% 116
2013
Q2
$395K Buy
+8,910
New +$398K 0.06% 111

Other funds holding MRK

Croft-Leominster's MRK Position: Q4 2017 in Review

Croft-Leominster sold out of Merck (MRK) in Q4 2017, closing a stake of 3,932 shares — an estimated $240K sold.

Croft-Leominster first reported a position in MRK in Q2 2013 and held it in 17 quarters. The position peaked at $453K in Q3 2014. 2,008 funds tracked by Wall St. Rank hold MRK as of Q4 2017.

  • Croft-Leominster reported no remaining Merck position as of Q4 2017 after selling out during the quarter.
  • Croft-Leominster sold 3,932 Merck shares in Q4 2017, an estimated $240K.
  • Croft-Leominster first reported a position in Merck in Q2 2013 and held it in 17 quarters.
  • Croft-Leominster's Merck position peaked at $453K in Q3 2014.
  • 2,008 funds tracked by Wall St. Rank held Merck as of Q4 2017.

Based on Croft-Leominster's 13F filing for Q4 2017, filed 6 Mar 2018.